Immunotherapy-Induced Vogt Koyanagi Harada Syndrome: A Case Report

This report describes a case of Vogt Koyanagi Harada Disease (VKH) in 44-year-old male with metastatic gastric carcinoma who presented sudden onset headache and decreased vision. The patient was treated first-line standard therapy for stage IV HER2-positive adenocarcinoma on maintenance trastuzumab pembrolizumab seven months before developing new symptoms. His VKH diagnosed after multiple imaging comprehensive ophthalmologic examination. patient’s vision headaches improved theinitiation corticosteroid therapy. Although immunotherapy wasdiscontinued,trastuzumab continuedwith close ophthalmology follow-up. He remains stable conditiondespitehis cancer. It is critical to consider recognize immunotherapy-relatedophthalmologic complications immediately, even if they are rare, considering theirimplications. Corticosteroids remain the organ-saving